NEW YORK (GenomeWeb News) – Veracyte today announced that private payor UnitedHealthcare has issued a positive medical coverage policy for the firm's molecular diagnostic test for thyroid cancer.

The decision by UHC, which covers about 27 million commercial members, pertains to Veracyte's Afirma Gene Expression Classifier for assessing thyroid nodule fine needle aspirate biopsies that are neither clearly benign nor malignant based on cytology review. The policy takes effect April 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.